Total survival didn’t enhance with Cyramza plus Lonsurf, in contrast with Lonsurf alonh Lonsurf alone, e, in sufferers with closely pretreated metastatic colorectal most cancers.
Including Cyramza (ramucirumab) to Lonsurf (trifluridine/tipiracil) didn’t considerably enhance survival in contrast with Lonsurf alone in closely pretreated metastatic colorectal most cancers (mCRC), in keeping with findings from the section 3 IKF-AIO-RAMTAS trial offered on the 2024 ESMO Congress.
Findings confirmed that the median general survival (the time when a affected person with most cancers continues to be alive; OS) was 7.46 months within the investigational arm (213 sufferers) versus 7.06 months within the management arm (215 sufferers), with a complete of 83.6% and 86.5% of occasions having occurred, respectively.
“The IKF-AIO-RAMTAS trial didn’t meet its major finish level of OS within the [intention-to-treat] inhabitants,” Dr. Stefan Kasper-Virchow, lead examine creator and professor of medical oncology at College Hospital Essen in Germany, stated in a presentation of the information. “Subgroups with profit had been feminine sufferers and sufferers with left-sided tumors.”
Research Highlights
- The first finish level of the trial, general survival, was not met. Which means that the mix of Cyramza and Lonsurf didn’t considerably lengthen the lives of sufferers with closely pretreated metastatic colorectal most cancers in comparison with Lonsurf alone.
- Whereas the general survival profit was not vital, the trial did establish subgroups which may profit from the mix. Feminine sufferers and people with left-sided tumors confirmed improved survival outcomes with Cyramza/Lonsurf.
- Though the mix didn’t enhance general survival, it did considerably lengthen progression-free survival, which means sufferers lived longer with out their illness worsening.
- The mix of Cyramza and Lonsurf was typically well-tolerated, with an identical security profile to Lonsurf alone. Nonetheless, there was the next incidence of treatment-related unwanted side effects, particularly these associated to Cyramza.
Outcomes from the subgroup evaluation indicated that the median OS in sufferers with left-sided tumors (287 sufferers; 67.1%) was 8.2 months with Cyramza/Lonsurf versus 6.9 months with Lonsurf alone. Feminine sufferers (193 sufferers; 45.1%) skilled a median OS of 9.3 months with Cyramza/Lonsurf versus 7.8 months with Lonsurf alone.
Lonsurf is permitted for the remedy of sufferers with chemotherapy-refractory mCRC, and Cyramza, a VEGFR2-directed antibody, is indicated to be used together with FOLFIRI (a chemotherapy routine with leucovorin calcium, fluorouracil and irinotecan hydrochloride) for the remedy of sufferers with mCRC following illness development on frontline FOLFOX (a chemotherapy routine with leucovorin calcium, fluorouracil and ocaliplatin) plus Avastin (bevacizumab). Coupled with the information that antiangiogenic brokers together with bevacizumab, aflibercept, Cyramza, Stivarga (regorafenib) and Fruzaqla (fruquintinib) have antitumor exercise in mCRC, investigators sought to judge the synergistic potential of Cyramza and Lonsurf.
IFK-AIO-RAMTAS is a trial that enrolled sufferers with superior mCRC following development or intolerance to fluoropyrimidines, oxaliplatin, irinotecan, antiangiogenic brokers together with Avastin, aflibercept, Cyramza, or Stivarga, and anti-EGFR antibodies if applicable. An ECOG efficiency standing of 0 or 1 (absolutely energetic or with some restrictions for bodily strenuous exercise) was required, and prior remedy with Lonsurf was not allowed.
Sufferers underwent random task to intravenous Cyramza and oral Lonsurf, or Lonsurf alone. Observe-up occurred each eight weeks.
The principle focus of the trial was to evaluate OS. Secondary finish factors had been progression-free survival (the time throughout and after remedy when a affected person with most cancers is alive with out illness worsening; PFS), goal response charge (the share of sufferers with an entire or partial response to remedy; ORR), illness management charge (DCR), security and high quality of life (QOL).
The baseline traits had been “equal in each arms and consultant for this affected person inhabitants,” Kasper-Virchow stated. Within the whole inhabitants (428 sufferers) the median age was 62 years and 45.1% of sufferers had been feminine. Most sufferers had been microsatellite secure (tumors with a comparatively regular variety of repetitive DNA sequences; 59.8%), had an ECOG efficiency standing of 0 (52.8%), a major tumor that was localized to the left facet (67.1%), and RAS-mutated (61.7%) and BRAF V600E wild-type illness (95.6%).
Relating to sufferers’ prior remedy historical past, within the general inhabitants the time from first metastasis to randomization was 23.9 months and the median variety of prior traces of remedy was three. Most sufferers had obtained at the least two prior traces of remedy (62.6%) and obtained prior antiangiogenic remedy (87.6%), the length of which was lower than 12 months typically (65.4%).
Further findings demonstrated a major enchancment in PFS with the mix, in keeping with Kasper-Virchow, at 2.37 months versus 2.07 months within the Lonsurf monotherapy arm, with 93.9% and 94.4% of occasions having occurred, respectively. The profit was noticed throughout “almost all” subgroups, Kasper-Virchow stated.
The ORR was 1.9% in each arms, “as anticipated in a closely pretreated affected person inhabitants,” although the DCR was “considerably improved” within the mixture arm, at 39.4% versus 31.6% with Lonsurf alone.
Relating to security, treatment-related unwanted side effects occurred in 85.8% of sufferers within the mixture arm versus 73.7% of these within the monotherapy arm. Grade 3 (extreme) or higher treatment-related unwanted side effects occurred in 55.9% and 36.8% of sufferers, respectively. Grade 3 or higher treatment-related unwanted side effects associated to Cyramza occurred in 39.3% of sufferers within the mixture arm, and grade 3 or higher treatment-related unwanted side effects associated to Lonsurf occurred in 48.8% and 36.8% of sufferers within the mixture and monotherapy arms, respectively.
Any facet impact of particular curiosity associated to Cyramza occurred in 28.9% of sufferers within the mixture arm –– primarily hypertension (hypertension) and proteinuria (excessive ranges of protein in urine) –– and treatment-related critical unwanted side effects occurred in 15.6% and 5.3% of sufferers within the mixture and monotherapy arms, respectively.
Within the mixture arm, 18.3% of sufferers required dose modification with Cyramza and extra sufferers required dose modification with Lonsurf, at 40.8% versus 24.2% within the monotherapy arm.
Therapy-related unwanted side effects that occurred in at the least 10% of sufferers within the mixture arm (211 sufferers) had been neutropenia (decrease than regular variety of neutrophils, a sort of white blood cell, in blood, which assist the physique in opposition to infections; all grade, 46.4%; grade ≥3, 32.2%), leukopenia (decrease than regular ranges of leukocytes, a sort of white blood cell; all grade, 22.7%; grade ≥3, 10.4%), fatigue (all grade, 20.9%; grade ≥3, 2.4%), nausea (all grade, 22.7%; grade ≥3, 0.9%) and diarrhea (all grade, 17.1%; grade ≥3, 2.8%). The charges of treatment-related unwanted side effects within the Lonsurf monotherapy arm had been comparable: neutropenia (all grade, 36.8%; grade ≥3, 22.0%), leukopenia (all grade, 19.1%; grade ≥3, 10.5%), fatigue (all grade, 19.1%; grade ≥3, 0.5%), nausea (all grade, 18.7%; grade ≥3, 1.0%) and diarrhea (all grade, 12.0%; grade ≥3, 2.4%).
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
